Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Aethlon Medical (Nasdaq:AEMD) reported Q1 fiscal 2027 results for the quarter ended June 30, 2026 and updated progress on its Hemopurifier® program. The company dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia, with preliminary biomarker observations from the first two cohorts showing decreases in tumor-derived extracellular vesicles and cancer‑linked microRNAs, and signs of improved immune function, all to be fully evaluated after study completion.
A Long COVID manuscript on extracellular vesicles was accepted in the International Journal of Molecular Sciences, demonstrating that Long COVID patient vesicles bind to the Hemopurifier’s GNA resin. Cash and cash equivalents were about $4.9 million on June 30, 2026, and Aethlon subsequently raised approximately $4.0 million in gross proceeds via a public stock offering. Operating expenses fell 11.9% year over year to roughly $1.6 million, and net loss attributable to common stockholders narrowed to about $1.55 million. The company believes its cash resources can fund operations for at least the next 12 months.
Aethlon Medical (Nasdaq: AEMD) will release fiscal first quarter results for the period ended June 30, 2026, at 4:15 p.m. ET on Thursday, August 13, 2026, followed by a conference call at 4:30 p.m. ET to review results and corporate developments.
According to Aethlon Medical, investors can pre-register online to receive dial-in details or join by phone using designated U.S. and international numbers. A replay will be available via phone and the company’s website through September 13, 2026 using conference ID 6711524. The company also highlights its FDA Breakthrough Device-designated Hemopurifier, a clinical-stage immunotherapeutic device being developed for advanced cancer, life-threatening viral infections, and organ transplantation applications.
Aethlon Medical (Nasdaq: AEMD) reported that patients in the second cohort of its Australian oncology feasibility study of the investigational Hemopurifier showed biological changes similar to those seen in the first cohort after treatment. Replicating these biomarker shifts supports continued enrollment of the third and final cohort, after which an independent statistician will analyze combined data for potential dose-response patterns.
The study evaluates safety, feasibility and dosing of Hemopurifier in patients with advanced solid tumors progressing despite anti-PD-1 immunotherapies. Observed changes include reductions in several extracellular vesicle populations and tumor-associated microRNAs, improvements in multiple immune-related laboratory ratios, and increases in total and tumor-specific T-cell populations. Aethlon highlights that these are preliminary, descriptive observations from an early-stage feasibility study, not designed to demonstrate clinical efficacy, and that larger, adequately powered trials will be needed to assess clinical benefit.
Aethlon Medical (Nasdaq:AEMD) priced a $4.0 million follow-on offering of 5,633,009 common shares (or pre-funded warrants) plus warrants to purchase 5,633,009 shares at $0.7101 per share and warrant, at-the-market under Nasdaq rules.
Warrants become exercisable upon stockholder approval and expire five years later. Closing is expected around July 7, 2026, with net proceeds earmarked for R&D, clinical trials, capital spending and working capital.
Aethlon Medical (Nasdaq:AEMD) announced peer-reviewed research identifying a novel Long COVID biomarker and target for its Hemopurifier® device. The study found significantly increased mannosylated extracellular vesicles (EVs) in Long COVID patients, which were captured using the same Galanthus nivalis agglutinin (GNA) affinity resin used in the Hemopurifier.
Key findings include roughly two-fold higher mannose-positive EVs in Long COVID, successful capture of disease-associated small EVs, significant reduction of seven immune-related microRNAs after GNA resin treatment, and pathway analysis implicating JAK-STAT, VEGF, PI3K, and estrogen signaling. The results support EVs as a potential therapeutic target and provide a translational framework for future Hemopurifier studies in Long COVID.
The editorial reviews how biotech and medical tech companies are responding to the 2026 Ebola/Bundibugyo virus outbreak, which has caused over 1,000 cases and 260 deaths. It highlights vaccine and therapeutic efforts by Soligenix (SNGX), Aethlon Medical (NASDAQ:AEMD), Regeneron (REGN), and Moderna (MRNA).
Soligenix and collaborators report thermostable multivalent filovirus vaccines with up to 100% protection in non-human primates. Aethlon’s Hemopurifier investigational device was used during the 2014 Ebola outbreak under emergency use. Regeneron’s maftivimab has been prioritized by WHO for Bundibugyo trials, while Moderna received up to $50 million from CEPI to advance an mRNA Bundibugyo vaccine.
Aethlon Medical (Nasdaq:AEMD) reported fiscal year ended March 31, 2026 results and a corporate update. The company advanced its Australian oncology trial into Cohort 3, with the first participant completing three Hemopurifier treatments without device deficiencies or immediate complications.
Aethlon expanded Hemopurifier intellectual property, including U.S. and European patents for Long COVID and acute COVID-19 coagulopathy extending into the 2040s, and advanced preclinical work in rheumatoid arthritis and chronic kidney disease. Operating expenses fell 21.9% to about $7.3 million, and net loss narrowed to $7.2 million. Cash was roughly $5.0 million, plus $1.85 million raised post year-end via an at-the-market program.
Aethlon Medical (Nasdaq:AEMD) will release fiscal year-end results for the period ended March 31, 2026 at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call at 4:30 p.m. ET, followed by a Q&A session, with replay available through July 10, 2026.
Aethlon Medical (NASDAQ:AEMD) is monitoring the current Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda and remains prepared to discuss potential investigational use of its Hemopurifier with global health and regulatory authorities.
The Hemopurifier is an investigational device designed to remove enveloped viruses. In a 2014 emergency-use case in Germany, a critically ill Ebola (Zaire strain) patient received a single 6.5-hour treatment, with reported viral load decline from ~400,000 to ~1,000 copies/mL and undetectable virus five days later. The FDA previously granted an IDE supplement enabling a regulatory pathway for investigational Hemopurifier use in Ebola patients in the U.S. The device remains investigational, and Aethlon will continue to monitor the outbreak and respond to clinician inquiries.
Aethlon Medical (NASDAQ: AEMD) announced the independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 trial on March 24, 2026 and recommended advancing to cohort 3. No device-related SAEs or DLTs were reported and cohort 3 enrollment is open to receive three Hemopurifier treatments over one week.
The study (9–18 patients) evaluates safety, feasibility and dose-finding in patients with solid tumors receiving pembrolizumab or nivolumab, with primary endpoints focused on adverse events and safety labs.